London, UK – November 3, 2025
Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company, has announced the grant of a new composition of matter patent in Japan for its lead compound, S-pindolol benzoate (ACM-001.1). This milestone further strengthens Actimed’s global intellectual property (IP) estate, reinforcing protection for one of the company’s most promising therapeutic candidates targeting muscle-wasting disorders such as cancer cachexia.
Science Significance
The newly issued Japanese patent for S-pindolol benzoate extends Actimed’s coverage beyond the U.S. and Europe, ensuring broad protection for the compound and its pharmaceutically acceptable forms. S-pindolol benzoate is a pro-anabolic and anti-catabolic transforming agent (ACTA), exhibiting a multi-modal mechanism of action that targets several biological pathways associated with muscle degradation and cachexia. This compound has shown promising Phase 2a proof-of-concept data in cancer patients and is currently being studied in the PROACT Phase 2a clinical trial, assessing its role in reducing muscle loss in obese patients treated with GLP-1 receptor agonists. These findings mark significant progress toward addressing the unmet need for effective muscle-preserving therapies in both cancer and obesity.
Regulatory Significance
The Japan Patent Office (JPO)’s grant of a composition of matter patent for S-pindolol benzoate represents a major regulatory milestone for Actimed. This form of patent protection—covering the core molecular structure—is considered the strongest category of intellectual property in pharmaceuticals. The Japanese approval not only validates the compound’s novelty and innovation but also extends market exclusivity in one of the largest global pharmaceutical markets. This robust IP position will support ongoing clinical development, regulatory filings, and future marketing authorizations in key territories worldwide.
Advertisement
Business Significance
For Actimed Therapeutics, this patent adds substantial value to its corporate and investor proposition, creating a competitive moat around S-pindolol benzoate. The company’s expanding patent portfolio now covers composition of matter and crystalline form patents across major jurisdictions, enhancing licensing, partnership, and commercialization potential. CEO Robin Bhattacherjee emphasized that the Japanese patent “significantly strengthens our global IP position” and reinforces Actimed’s mission to deliver first-in-class therapies for muscle-wasting diseases. As Actimed progresses its development programs, such comprehensive IP protection will underpin both scientific and financial sustainability, positioning the company as a leader in muscle health innovation.
Patients’ Significance
For patients suffering from cancer cachexia or muscle-wasting linked to chronic conditions, the potential impact of S-pindolol benzoate is profound. Cachexia leads to severe weight and muscle loss, reducing treatment tolerance and survival rates. Despite its prevalence, no globally approved therapies exist to treat or prevent cancer cachexia. Moreover, in obese patients using GLP-1 receptor agonists, unwanted lean muscle reduction often accompanies fat loss. Actimed’s compound aims to preserve healthy muscle mass while supporting beneficial metabolic effects—potentially improving quality of life, functional outcomes, and survival across multiple disease settings.
Policy Significance
The strengthening of Actimed’s IP position aligns with global innovation policy goals that encourage biomedical R&D and therapeutic discovery. By obtaining strong composition of matter protection in Japan, Actimed contributes to the international framework of pharmaceutical innovation, where patent exclusivity incentivizes long-term investment in high-risk clinical programs. The development of muscle-preserving therapies also supports public health priorities in aging populations, oncology care, and obesity management, where muscle loss significantly affects morbidity and healthcare costs.
The grant of Japan’s composition of matter patent for S-pindolol benzoate (ACM-001.1) marks a pivotal advancement in Actimed Therapeutics’ global IP and development strategy. With patents now secured in the U.S., Europe, and Japan, Actimed is well-positioned to advance clinical trials, expand collaborative opportunities, and deliver novel therapies for patients facing muscle-wasting diseases. As the company’s science-driven pipeline matures, this achievement reinforces its leadership in muscle health innovation and commitment to transforming care in cachexia and related disorders.
Source : Actimed Therapeutics press release
